Is ImmuCell Stock a Good Investment?
ImmuCell Investment Advice | ICCC |
- Examine ImmuCell's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ImmuCell's leadership team and their track record. Good management can help ImmuCell navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ImmuCell's business and its evolving consumer preferences.
- Compare ImmuCell's performance and market position to its competitors. Analyze how ImmuCell is positioned in terms of product offerings, innovation, and market share.
- Check if ImmuCell pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ImmuCell's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ImmuCell stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ImmuCell is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ImmuCell Stock
Researching ImmuCell's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 40.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.39. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity recorded a loss per share of 0.49. The firm had not issued any dividends in recent years. ImmuCell had 1:100 split on the 25th of July 1990.
To determine if ImmuCell is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ImmuCell's research are outlined below:
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| ImmuCell has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: ImmuCell Q3 Earnings Decline YY, Sales Grow Amid Margin Challenges - MSN |
ImmuCell Quarterly Liabilities And Stockholders Equity |
|
ImmuCell uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ImmuCell. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ImmuCell's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact ImmuCell's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ImmuCell's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-12 | 2020-06-30 | -0.1 | -0.11 | -0.01 | 10 | ||
2020-11-12 | 2020-09-30 | -0.08 | -0.04 | 0.04 | 50 | ||
2021-02-22 | 2020-12-31 | -0.04 | 0.03 | 0.07 | 175 | ||
2021-10-06 | 2021-09-30 | -0.06 | 0.02 | 0.08 | 133 | ||
2021-08-12 | 2021-06-30 | -0.08 | 0.02 | 0.1 | 125 | ||
2021-05-13 | 2021-03-31 | 0.05 | -0.06 | -0.11 | 220 |
Know ImmuCell's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmuCell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmuCell backward and forwards among themselves. ImmuCell's institutional investor refers to the entity that pools money to purchase ImmuCell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Susquehanna International Group, Llp | 2024-06-30 | 20.8 K | Prosperity Planning, Inc. | 2024-09-30 | 16 K | Blackrock Inc | 2024-06-30 | 13.8 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12.2 K | Essex Financial Services, Inc. | 2024-06-30 | 11 K | Hm Payson & Co | 2024-09-30 | 4 K | Ubs Group Ag | 2024-06-30 | 2.7 K | Bank Of America Corp | 2024-06-30 | 2.1 K | Tower Research Capital Llc | 2024-06-30 | 1.8 K | Cresset Asset Management, Llc | 2024-09-30 | 264 K | Vanguard Group Inc | 2024-09-30 | 225.6 K |
ImmuCell's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.08 M.Market Cap |
|
ImmuCell's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.15) | (0.14) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.23) | (0.22) |
Determining ImmuCell's profitability involves analyzing its financial statements and using various financial metrics to determine if ImmuCell is a good buy. For example, gross profit margin measures ImmuCell's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ImmuCell's profitability and make more informed investment decisions.
Please note, the presentation of ImmuCell's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmuCell's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ImmuCell's management manipulating its earnings.
Evaluate ImmuCell's management efficiency
ImmuCell has return on total asset (ROA) of (0.0487) % which means that it has lost $0.0487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.161) %, meaning that it created substantial loss on money invested by shareholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.13. The current year's Return On Capital Employed is expected to grow to -0.14. At present, ImmuCell's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 36.5 B, whereas Non Currrent Assets Other are forecasted to decline to about 54.8 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.25 | 2.10 | |
| Tangible Book Value Per Share | 3.23 | 2.06 | |
| Enterprise Value Over EBITDA | (21.93) | (23.02) | |
| Price Book Value Ratio | 1.57 | 1.79 | |
| Enterprise Value Multiple | (21.93) | (23.02) | |
| Price Fair Value | 1.57 | 1.79 | |
| Enterprise Value | 54.9 M | 57.6 M |
ImmuCell showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 0.567 |
Basic technical analysis of ImmuCell Stock
As of the 1st of December, ImmuCell retains the Downside Deviation of 2.1, market risk adjusted performance of (0.19), and Risk Adjusted Performance of 0.0565. ImmuCell technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.ImmuCell's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmuCell insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmuCell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmuCell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ImmuCell's Outstanding Corporate Bonds
ImmuCell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ImmuCell uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ImmuCell bonds can be classified according to their maturity, which is the date when ImmuCell has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand ImmuCell's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ImmuCell's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0565 | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 1.58 | |||
| Semi Deviation | 1.85 | |||
| Downside Deviation | 2.1 | |||
| Coefficient Of Variation | 1532.2 | |||
| Standard Deviation | 2.25 | |||
| Variance | 5.08 | |||
| Information Ratio | 0.0042 | |||
| Jensen Alpha | 0.2263 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0045 | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 8.67 | |||
| Value At Risk | (3.02) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 4.4 | |||
| Semi Variance | 3.42 | |||
| Expected Short fall | (1.73) | |||
| Skewness | 1.46 | |||
| Kurtosis | 6.46 |
| Risk Adjusted Performance | 0.0565 | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 1.58 | |||
| Semi Deviation | 1.85 | |||
| Downside Deviation | 2.1 | |||
| Coefficient Of Variation | 1532.2 | |||
| Standard Deviation | 2.25 | |||
| Variance | 5.08 | |||
| Information Ratio | 0.0042 | |||
| Jensen Alpha | 0.2263 | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | 0.0045 | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 8.67 | |||
| Value At Risk | (3.02) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 4.4 | |||
| Semi Variance | 3.42 | |||
| Expected Short fall | (1.73) | |||
| Skewness | 1.46 | |||
| Kurtosis | 6.46 |
Consider ImmuCell's intraday indicators
ImmuCell intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ImmuCell stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ImmuCell Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of September 2024 Other Reports | ViewVerify | |
F3 | 27th of August 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
ImmuCell Stock media impact
Far too much social signal, news, headlines, and media speculation about ImmuCell that are available to investors today. That information is available publicly through ImmuCell media outlets and privately through word of mouth or via ImmuCell internal channels. However, regardless of the origin, that massive amount of ImmuCell data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ImmuCell news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ImmuCell relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ImmuCell's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ImmuCell alpha.
ImmuCell Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ImmuCell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
When determining whether ImmuCell offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ImmuCell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immucell Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immucell Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share 2.991 | Quarterly Revenue Growth 0.549 | Return On Assets (0.05) |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between ImmuCell's value and its price, as these two are different measures arrived at by various means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.